Format

Send to

Choose Destination
Aust Prescr. 2016 Aug;39(4):131-134. Epub 2016 Aug 1.

Rituximab in autoimmune diseases.

Author information

1
Department of Immunology, Canberra Hospital.

Abstract

Rituximab is a monoclonal antibody that depletes B cells from the circulation. It was originally used to treat lymphoma but is increasingly used for the treatment of autoimmune diseases. Rituximab was found to be effective in randomised controlled trials for rheumatoid arthritis, granulomatosis with polyangiitis and other antineutrophil cytoplasmic antibody-associated vasculitides. However, evidence of efficacy is very limited for many other autoimmune conditions. Before starting rituximab, it is important to check the patient's baseline immunoglobulins and immunisation status. Patients should also be screened for latent infections and other contraindications.

KEYWORDS:

B lymphocyte; antineoplastic agent; antineutrophil cytoplasmic antibody; autoantibody; lymphoma; rituximab

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center